Sanofi India Limited (SANOFI) Price & Analysis

Compare

12 Followers

SANOFI Stock Chart & Stats

₹4142.75

₹54.40(0.91%)

At close: Jan 08 4:00 PM EST

₹4142.75

₹54.40(0.91%)

Day’s Range― - ―

52-Week Range₹3,965.55 - ₹6,717.50

Previous CloseN/A

Volume15.46K

Average Volume (3M)3.77K

Market Cap

₹92.30B

Enterprise Value₹89.98B

Total Cash (Recent Filing)₹3.13B

Total Debt (Recent Filing)₹209.00M

Price to Earnings (P/E)25.9

Beta0.81

Next Earnings

Feb 25, 2026

EPS Estimate

45.05

Next Dividend Ex-DateN/A

Dividend Yield4.73%

Share Statistics

EPS (TTM)43.35

Shares Outstanding23,030,000

10 Day Avg. Volume3,778

30 Day Avg. Volume3,766

Financial Highlights & Ratios

PEG Ratio-2.44

Price to Book (P/B)16.38

Price to Sales (P/S)7.00

P/FCF Ratio33.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet HealthVery low leverage provides durable financial flexibility to fund R&D, regulatory compliance and working capital through cycles. This reduces insolvency risk, enables opportunistic capex or M&A, and underpins operational stability in a capital‑intensive pharma environment.

Cash Flow GenerationStrong free cash flow and high FCF-to-net-income support dividends, reinvestment and organic growth without reliance on external financing. Reliable cash conversion buffers the business against revenue volatility and funds product launches and marketing over the medium term.

Chronic & Consumer PortfolioA mix of chronic prescription therapies and consumer health brands creates recurring demand and brand loyalty. Chronic-care products generally produce predictable prescription volumes, reducing revenue cyclicality and supporting steady cash flows and market position over multiple quarters.

Bears Say

Revenue Growth TrendA near‑20% revenue decline signals weakening sales momentum and potential loss of market share or product demand. If this trend persists it can erode operating leverage, restrict reinvestment in key therapies, and weaken the firm's competitive footing over the medium term.

Margin VolatilityDeclining and volatile margins point to rising non‑operational costs or pressure on pricing and cost control. Persistent margin compression would reduce cash available for R&D, marketing and capex, undermining long‑term profitability and strategic investments.

Erosion Of Equity BufferA shrinking equity base, even modest, reduces the capital cushion to absorb shocks or fund growth. Continued declines could constrain balance‑sheet capacity for acquisitions, larger capex or regulatory compliance spending, limiting strategic flexibility over coming quarters.

Sanofi India Limited News

Sanofi India Faces GST Demand Order of Rs 35.63 Lakh, Plans to Appeal

The latest update is out from Sanofi India Limited ( ($IN:SANOFI) ). Sanofi India Limited has disclosed that...

2M ago

Sanofi India Announces Key Leadership Changes

Sanofi India Limited ( ($IN:SANOFI) ) has provided an update. Sanofi India Limited announced a change in its...

4M ago

Sanofi India Announces Leadership Changes with New Managing Director Appointment

Sanofi India Limited ( ($IN:SANOFI) ) has issued an update. Sanofi India Limited announced the cessation of Mr....

4M ago

Sanofi India Appoints New Managing Director

Sanofi India Limited ( ($IN:SANOFI) ) has shared an announcement. Sanofi India Limited has announced the appointment of...

4M ago

Sanofi India Schedules Investor Call to Discuss Financial Results

Sanofi India Limited ( ($IN:SANOFI) ) has provided an update. Sanofi India Limited has announced an investor and...

4M ago

Sanofi India Announces Key Management Change

Sanofi India Limited ( ($IN:SANOFI) ) just unveiled an announcement. Sanofi India Limited has announced a key change...

5M ago

Sanofi India Launches ‘Saksham Niveshak’ Campaign to Engage Shareholders

An announcement from Sanofi India Limited ( ($IN:SANOFI) ) is now available. Sanofi India Limited has announced a...

6M ago

Sanofi India Reports Growth in Operating Profit Amid Sales Decline

Sanofi India Limited ( ($IN:SANOFI) ) has issued an update. Sanofi India Limited reported a 2% decline in...

7M ago

Sanofi India Limited Announces Financial Results and Leadership Changes

Sanofi India Limited ( ($IN:SANOFI) ) has provided an update. Sanofi India Limited announced the approval of its...

7M ago

Sanofi India Announces Trading Window Closure Ahead of Financial Results

An update from Sanofi India Limited ( ($IN:SANOFI) ) is now available. Sanofi India Limited has announced the...

8M ago

SANOFI FAQ

What was Sanofi India Limited’s price range in the past 12 months?

Sanofi India Limited lowest stock price was ₹3965.55 and its highest was ₹6717.50 in the past 12 months.

What is Sanofi India Limited’s market cap?

Sanofi India Limited’s market cap is ₹92.30B.

When is Sanofi India Limited’s upcoming earnings report date?

Sanofi India Limited’s upcoming earnings report date is Feb 25, 2026 which is in 2 days.

How were Sanofi India Limited’s earnings last quarter?

Sanofi India Limited released its earnings results on Oct 29, 2025. The company reported ₹43.35 earnings per share for the quarter, beating the consensus estimate of ₹38.4 by ₹4.95.

Is Sanofi India Limited overvalued?

According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sanofi India Limited pay dividends?

Sanofi India Limited pays a Semiannually dividend of ₹75 which represents an annual dividend yield of 4.73%. See more information on Sanofi India Limited dividends here

What is Sanofi India Limited’s EPS estimate?

Sanofi India Limited’s EPS estimate is 45.05.

How many shares outstanding does Sanofi India Limited have?

Sanofi India Limited has 23,030,000 shares outstanding.

What happened to Sanofi India Limited’s price movement after its last earnings report?

Sanofi India Limited reported an EPS of ₹43.35 in its last earnings report, beating expectations of ₹38.4. Following the earnings report the stock price went down -0.37%.

Which hedge fund is a major shareholder of Sanofi India Limited?

Currently, no hedge funds are holding shares in IN:SANOFI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sanofi India Limited

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.